Effective Friday, May 3rd, 2024, Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd, has acquired global rights to lonafarnib (Zokinvy) from Eiger BioPharmaceuticals (Eiger). Zokinvy® is provided to families worldwide who are using the drug as a treatment for progeria.
Based in San Diego, California, Sentynl is focused on providing novel biopharmaceutical medicines that extend, improve, or enhance the lives of people with rare disease (https://sentynl.com/). PRF is thankful for the successful partnership with Eiger, and excited to now join forces with Sentynl. PRF will work closely with them, as we did with Eiger, to assist in the company’s efforts to ensure uninterrupted supply of Zokinvy for patients around the world.
A link to Sentynl’s press release on this news can be found כָּאן.
Hebrew 
English 
Arabic 
Bengali 
Chinese 
Dutch 
French 
German 
Hindi 
Indonesian 
Italian 
Kannada 
Kazakh 
Korean 
Marathi 
Pashto 
Portuguese 
Russian 
Spanish 
Tamil 
Ukrainian 
Urdu